Metastatic Urothelial Carcinoma Clinical Trials

19 recruiting

Metastatic Urothelial Carcinoma Trials at a Glance

20 actively recruiting trials for metastatic urothelial carcinoma are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Chicago, Atlanta, and Irvine. Lead sponsors running metastatic urothelial carcinoma studies include Mayo Clinic, National Cancer Institute (NCI), and Vasgene Therapeutics, Inc.

Browse metastatic urothelial carcinoma trials by phase

Treatments under study

About Metastatic Urothelial Carcinoma Clinical Trials

Looking for clinical trials for Metastatic Urothelial Carcinoma? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Urothelial Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Urothelial Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 20 trials

Recruiting
Phase 3

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma
National Cancer Institute (NCI)320 enrolled129 locationsNCT06524544
Recruiting
Phase 1

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma+1 more
Emory University32 enrolled1 locationNCT04878029
Recruiting
Phase 2

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Endometrial CancerLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+10 more
Rahul Aggarwal89 enrolled3 locationsNCT03682289
Recruiting
Not Applicable

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

Metastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Renal Cell Carcinoma+15 more
M.D. Anderson Cancer Center40 enrolled1 locationNCT04693377
Recruiting
Phase 1

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Metastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma
National Cancer Institute (NCI)27 enrolled11 locationsNCT06439836
Recruiting
Phase 1

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Metastatic Urothelial CarcinomaAdvanced Urothelial Cancer
Generate Biomedicines37 enrolled2 locationsNCT07484022
Recruiting
Phase 1

Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma

Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Urothelial Carcinoma+2 more
Beijing Biotech42 enrolled1 locationNCT07492628
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 4

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

Metastatic Urothelial Carcinoma
Astellas Pharma Global Development, Inc.100 enrolled10 locationsNCT06862219
Recruiting
Phase 3

A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma

Locally Advanced or Metastatic Urothelial Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.462 enrolled1 locationNCT07393542
Recruiting
Phase 2

Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma

Metastatic Urothelial CarcinomaUnresectable Urothelial CarcinomaAdvanced Urothelial Carcinoma
Fox Chase Cancer Center97 enrolled1 locationNCT07221942
Recruiting

A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma

Urothelial CarcinomaMetastatic Urothelial CarcinomaNeuropathy
Memorial Sloan Kettering Cancer Center50 enrolled7 locationsNCT07390617
Recruiting
Not Applicable

An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

Urothelial CarcinomaMetastatic Urothelial CarcinomaRenal Cell Carcinoma+9 more
University of Texas Southwestern Medical Center600 enrolled1 locationNCT04623502
Recruiting

Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma

Metastatic Urothelial Carcinoma
University Hospital, Strasbourg, France50 enrolled1 locationNCT07339878
Recruiting
Phase 2

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Urothelial CarcinomaEsophageal CarcinomaHepatocellular Carcinoma+28 more
Mayo Clinic50 enrolled1 locationNCT06265285
Recruiting
Phase 1Phase 2

Sacituzumab Govitecan Plus EV in Metastatic UC

Metastatic Urothelial CarcinomaUrothelial CancerBladder Cancer+1 more
Dana-Farber Cancer Institute106 enrolled1 locationNCT04724018
Recruiting
Phase 2Phase 3

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Metastatic Urothelial CarcinomaMuscle-Invasive Bladder Carcinoma
Vasgene Therapeutics, Inc700 enrolled1 locationNCT06493552
Recruiting
Phase 2

A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma

Metastatic Urothelial Carcinoma
Vasgene Therapeutics, Inc38 enrolled1 locationNCT04486781
Recruiting

Urine Omics Predicting IO Therapy Responses in mUC Patients

Metastatic Urothelial Carcinoma
National Taiwan University Hospital600 enrolled1 locationNCT04641936
Recruiting
Phase 2

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Metastatic Gastroesophageal Junction Adenocarcinoma+30 more
Northwestern University94 enrolled1 locationNCT05733000